


RealRate

Qualigen Therapeutics Inc. Rank 51 of 342











Qualigen Therapeutics Inc. Rank 51 of 342



The relative strengths and weaknesses of Qualigen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Qualigen Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 126% points. The greatest weakness of Qualigen Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 209%, being 164% points above the market average of 46%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 22,799               |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 2,708                |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 10                   |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 250                  |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 39                   |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 24                   |
| Research and Development                    | 2,874                |
| Selling, General and Administrative Expense | 4,778                |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 22,834               |
| Liabilities              | 2,708                |
| Expenses                 | 7,902                |
| Revenues                 | 0                    |
| Stockholders Equity      | 20,126               |
| Net Income               | -7,864               |
| Comprehensive Net Income | -7,864               |
| Economic Capital Ratio   | 209%                 |

